Organisation paid for research Program year 2025 Source: CMS Open Payments

Cedar Health Research

Neither a doctor nor a teaching hospital

Research payments

$3,003,166

144 payments

Through program year 2025, Cedar Health Research is reported as receiving $3,003,166 in research payments, across 144 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,063,288 39
2024 Research $1,014,919 41
2023 Research $495,301 13
2022 Research $251,961 30
2021 Research $177,696 21

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $2,059,035 32 payments
  2. Sanofi Pasteur Inc. $182,593 17 payments
  3. Mylan Technologies Inc. $182,101 5 payments
  4. Sanofi US Services Inc. $171,044 10 payments
  5. GlaxoSmithKline, LLC. $115,085 7 payments
  6. Mylan Inc. $66,467 2 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $59,849 13 payments
  8. AstraZeneca Pharmaceuticals LP $48,058 4 payments
  9. Biohaven Pharmaceuticals, Inc. $41,388 13 payments
  10. Pfizer Inc. $21,276 14 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $1,090,600 9 payments
  2. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $392,747 2 payments
  3. A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $349,693 5 payments
  4. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $349,633 26 payments
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $197,854 6 payments
  6. Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $182,101 5 payments
  7. A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $115,085 7 payments
  8. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $66,467 2 payments
  9. a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older $33,060 2 payments
  10. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $31,760 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record